Results from the pivotal CREDENCE trial, investigating canagliflozin for renal and cardiovascular outcomes in type 2 diabetes with nephropathy, were published on 2019-01-01. This publication details the evaluation of the drug's effects in this patient population.
Background
Canagliflozin is a medication used in the management of type 2 diabetes. The CREDENCE trial specifically investigated its effects in patients who also have diabetic nephropathy, a serious complication of diabetes characterized by kidney damage.
Trial design
The CREDENCE trial, titled "Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy," was designed to assess the impact of canagliflozin on renal and cardiovascular endpoints. The study population included participants with type 2 diabetes and established diabetic nephropathy, aiming to understand the drug's role in mitigating disease progression in this high-risk group.
What this means
The publication of the CREDENCE trial results provides clinicians and researchers with detailed information regarding canagliflozin's effects on renal and cardiovascular outcomes in patients with type 2 diabetes and diabetic nephropathy. This pivotal study contributes to the understanding of treatment strategies for managing these complex conditions and their associated risks.
Source
The information regarding this pivotal publication was sourced from PubMed, an archive of biomedical and life sciences journal literature. The article, titled "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy", was published on 2019-01-01 in the New England Journal of Medicine and is accessible via pubmed.ncbi.nlm.nih.gov.